18 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
in settings with high dengue disease burden and high transmission intensity to maximize the public health impact and minimize any potential risk
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 23
Current report (foreign)
6:01am
in the U.S. in prior year, increasing global competitive intensity, and pricing headwinds in EUCAN. In the U.S., ENTYVIO maintains the lead as #1 in both IBD
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
transmission intensity to maximize the public health impact and minimize any potential risk in seronegative persons.
–The vaccine to be introduced
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
23 Jun 23
Current report (foreign)
6:13am
with ICLUSIG plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-negative complete remission (CR) compared … the efficacy and safety of two tyrosine kinase inhibitor (TKIs) in combination with reduced-intensity chemotherapy as a frontline therapy for adult patients
6-K
EX-99.1
i92qp t744p4e0jv2
30 May 23
Current report (foreign)
6:11am
6-K
EX-99.1
jcprg4ksjs 2rl8es
6 Apr 21
Current report (foreign)
6:29am
6-K
EX-99.1
1ipi88yaflqvl7rjd
8 Dec 20
Current report (foreign)
6:01am
424B3
7ksqwnw5 4fer
14 Nov 19
Prospectus supplement
6:10am
F-4/A
bhyq8
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
F-4
phb5mmgh01
9 Aug 19
Registration of securities (foreign)
6:27am
20-F
rth6 1lu5
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
7p9 y6wh8
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
4dtdnp7gjusa4 j5cuo
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
8ji39x0 mcha4e34s
16 Nov 18
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next